Alex Panaccione
Principal Medical Science Liaison, Oncology, Solid Tumor @Johnson & Johnson Innovative Medicine
Signup · Get unlimited contacts
WORK HISTORY
Principal Medical Science Liaison, Oncology, Solid Tumor @Johnson & Johnson Innovative Medicine
Managed U.S. MSL team coordination with cross-functional partners including global medical affairs, global clinical operations, and U.S. medical, and commercial teams as Compound Lead• Launched RYBREVANT (amivantamab-vmjw) and LAZCLUZE (lazertinib) for 1st line common EGFRm NSCLC• Launched RYBREVANT (amivantamab-vmjw) in combination with carboplatin & pemetrexed for indications in (1) 1st Line EGFR exon 20 insertion mutation NSCLC (2) 2nd line common EGFRm NSCLC post osimertinib• Shaped U.S. lung strategy as participant in integrated evidence team and commercial KOL workshops• Developed and led advisory boards with national and international academic & community KOLs• Authored two publications on real-world treatment outcomes of amivantamab from the global preapproval access program as recognition for contribution in stretch assignment with Global Medical Affairs
EDUCATION
Emory University
Bachelor of Science (B.S.) Biology & Bachelor of Science (B.S.) Chemistry
Vanderbilt University
Doctor of Philosophy (Ph.D.) Cancer Biology
ABOUT ALEX PANACCIONE
Principal Medical Science Liaison at The Janssen Pharmaceutical Companies of Johnson & Johnson
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.